Treatment of immunodeficiency with interleukin-2: initial exploration.
about
The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatmentProlonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection.Interleukin 2 enhances specific and nonspecific immune responses in experimental Chagas' diseaseNatural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients.
P2860
Treatment of immunodeficiency with interleukin-2: initial exploration.
description
1984 nî lūn-bûn
@nan
1984 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
Treatment of immunodeficiency with interleukin-2: initial exploration.
@ast
Treatment of immunodeficiency with interleukin-2: initial exploration.
@en
Treatment of immunodeficiency with interleukin-2: initial exploration.
@nl
type
label
Treatment of immunodeficiency with interleukin-2: initial exploration.
@ast
Treatment of immunodeficiency with interleukin-2: initial exploration.
@en
Treatment of immunodeficiency with interleukin-2: initial exploration.
@nl
prefLabel
Treatment of immunodeficiency with interleukin-2: initial exploration.
@ast
Treatment of immunodeficiency with interleukin-2: initial exploration.
@en
Treatment of immunodeficiency with interleukin-2: initial exploration.
@nl
P2093
P1476
Treatment of immunodeficiency with interleukin-2: initial exploration.
@en
P2093
Clarkson BD
Mertelsmann R
O'Reilly R
Oettgen HF
Sternberg C
P304
P577
1984-10-01T00:00:00Z